Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Hsu, MA
Eugene Hsu, Somerville, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120101790 | EMBROIDERY IMAGE RENDERING USING PARAMETRIC TEXTURE MAPPING - Rendering methods, systems, and computer-readable media for rendering a simulated embroidery design image based on an embroidery design are presented. Given an embroidery design comprising a plurality of stitch representations and a lighting angle for the simulated embroidery design image, embodiments process the stitch representations to determine a stitch length and lighting angle and select from a stitch image database a stitch image corresponding to the stitch length and lighting angle, and place the selected stitch on a rendering canvas in a position corresponding to the stitch position indicated by the stitch representation. When rendered, all of individual stitch image on the rendering canvas appear to be illuminated from the same direction. | 04-26-2012 |
Eugene Hsu, Cambridge, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120120372 | SYSTEM AND METHOD FOR CALIBRATING A DISPLAY SYSTEM USING MANUAL AND SEMI-MANUAL TECHNIQUES - The invention provides a system and method that reduces the tediousness of the manual alignment process. Users select correspondences between projectors or components of a projector, to form a common coordinate. Using models of the display system, and projectors, the common coordinate system can be mapped quickly to the entire display. The process avoids a need to measure screen points, and allows the user to move significantly fewer points. Alternatively, the invention allows introduction of machine-vision style algorithms into manual calibration techniques to improve performance. This overcomes the tediousness of prior systems by introducing models of the display into the manual alignment process, allowing selection of a small number of points on each projector, and avoiding selection of precisely measured screen points. The system conversely finds correspondences between projectors, allowing mapping of the projectors into a common coordinate system, and quick warping of the coordinate system to the screen. | 05-17-2012 |
Hsun-Wen Hsu, Woburn, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20080219927 | ADENOSINE DERIVATIVE FORMULATIONS FOR MEDICAL IMAGING - A stable composition useful for myocardial perfusion imaging contains one or more 2-alkynyladenosine derivatives; and a solvent which is made up of water and hydroxypropyl-β-cyclodextrin. | 09-11-2008 |
Ming F. Hsu, Somerville, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20100213628 | METHODS AND COMPOSITIONS FOR ENCAPSULATING ACTIVE AGENTS - Methods for making self-assembled, selectively permeable elastic microscopie structures, referred to herein as colloidosomes, that have controlled pore-size, porosity and advantageous mechanical properties are described. In one form of the invention, a method of forming colloidosomes includes providing particles formed from a biocompatible material in a first solvent and forming an emulsion by adding a first fluid to the first solvent wherein the emulsion is defined by droplets of the first fluid surrounded by the first solvent. The method includes coating the surface of droplet with the particles and the stabilizing the particles on the surface of droplet. The colloidosomes produced typically have a yield strength of at least about 20 Pascals. In certain forms of the invention, the particles are spherical and are formed of a biocompatible polymer. Colloidosomes formed according to the methods described herein are also provided. In one form, a colloidosome includes a shell formed of biocompatible, substantially spherical particles wherein each of the particles are linked to neighboring particles. The shell defines an inner chamber sized for housing a desired active agent and has a plurality of pores extending therethrough. The colloidosomes are structurally stable, typically having a yield strength of at least about 20 Pascals. Colloidal suspension and methods of encapsulating a desired active agent are also described | 08-26-2010 |
Shaw Ling Hsu, Sunderland, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090240325 | Implantable Medical Device Coatings With Improved Mechanical Stability - Implantable medical device coatings that have improved mechanical stability and medical devices coated with such coatings are disclosed. | 09-24-2009 |
Yen-Ming Hsu, Lexington, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20080268480 | Methods of Evaluating Baff - The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject. | 10-30-2008 |
| 20090220998 | Platelet Aggregation Assays - The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto. | 09-03-2009 |
| 20090324602 | ANTI-FN14 ANTIBODIES AND USES THEREOF - Antibodies and antibody fragments that bind to the receptor Fn14 and induce or enhance cell killing of Fn14-expressing cancer cells are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a tumor cell and treat disorders and in a subject. | 12-31-2009 |
| 20100104573 | BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF - This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions. | 04-29-2010 |
| 20100184951 | Truncated BAFF Receptors - The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders. | 07-22-2010 |
| 20100330066 | Methods for Use with Baff Antagonists - BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-κB2, CD23, H2-Mβ (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-Mβ molecule in a biological sample of the mammal, and optionally further detecting NF-κB2 molecule and/or CD23 molecule in the biological sample. | 12-30-2010 |
| 20110311530 | TRUNCATED BAFF RECEPTORS - The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders. | 12-22-2011 |
| 20120082661 | ANTI-BCMA ANTIBODIES - This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases. | 04-05-2012 |